What changed for Asthma
A plain English summary of what recently moved in the public data Voxsanity tracks for Asthma. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 229 to 240 (+11)
- Late-stage (Phase 3) trials 27 to 28 (+1)
- Trials on record 3,316 to 3,390 (+74)
Newly subsidised on the PBS
1 medicine newly subsidised on the PBS for Asthma in July 2026:
- Tezepelumab
"Newly subsidised" means the medicine reached the PBS this month, not that a new pack size or brand of an existing listing was added. Verify current PBS status with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 179 trials tracked for Asthma that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04609878 · results posted 30 June 2026
According to the results reported on ClinicalTrials.gov, this trial (known as KALOS) enrolled 2,144 adults with asthma across four treatment groups. The groups tested two different dose combinations of a triple-ingredient inhaler called BGF MDI (at lower and higher doses of one ingredient), a double-ingredient inhaler called BFF MDI, and a commonly used comparator inhaler called Symbicort. The trial ran for 24 weeks and primarily measured two things: changes in lung function (specifically how much air participants could forcefully breathe out in one second, known as FEV1) and the rate of sever...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03926741 · results posted 20 May 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 48 people in total — 10 healthy participants and 38 with asthma. The study was investigating how the lungs process a substance called GSNO (S-nitrosoglutathione), which occurs naturally in the airways. To do this, researchers measured two things in participants' breath and lung function: the level of nitric oxide in exhaled breath (called FeNO, a by-product of GSNO breakdown), and the amount of air a person can forcefully breathe out in one second (called FEV1, a standard check of how well the lungs are working). All...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04718389 · results posted 18 May 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04718389) enrolled 859 people in the depemokimab group and 858 people in the comparison group, who received either mepolizumab or benralizumab — all existing asthma medicines given by injection under the skin. The trial ran for 52 weeks and was designed to compare how often participants in each group experienced serious asthma flare-ups (defined as episodes needing steroid medicines, a hospital stay, or an emergency department visit). Around 763–772 people in each group completed the full study period. The reported data s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00861926 · results posted 7 May 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 857 participants in each of two groups — a total of 1,714 people — all of whom had asthma. One group used an inhaler called Foster (Treatment A) on its own, while the other group used Foster together with a reliever inhaler called Ventolin (Treatment B). The trial was primarily measuring how long it took before participants had a severe asthma flare-up, defined as a flare-up serious enough to require a hospital visit, an emergency room visit, or at least three days of steroid tablets. The reported data shows that the...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02296411 · results posted 22 April 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT02296411) involved 98 people in total — 50 in one group and 48 in the other. It used a "crossover" design, meaning each participant received both the active inhaler (CHF5259 pMDI) and a placebo inhaler at different times, in a different order. The trial was measuring lung function, specifically how much air a person could forcefully breathe out in one second (known as FEV1). Researchers tracked this over 12 hours after a dose, on both the first day and after 42 days of use. The reported data shows that on Day 42, the aver...
-
NCT05091385 · results posted 28 January 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 106 adults with severe asthma in Poland who were receiving treatment with a biological medicine called mepolizumab through a national drug programme. All 106 participants completed the study. The trial tracked several things over 52 weeks, including how often participants had serious asthma flare-ups, how many needed daily steroid tablets, and scores from questionnaires about asthma control and quality of life, as well as a breathing test and a blood cell count. The reported data shows that in the year before treatme...
-
NCT05243680 · results posted 15 January 2026
According to the results reported on ClinicalTrials.gov, this extension trial (NCT05243680) enrolled 641 participants in total — 214 who had previously received a placebo in earlier studies, and 427 who had previously received the study drug, GSK3511294 (given as an injection under the skin). Both groups then received GSK3511294 100 mg injections during this extension phase. The trial was measuring tolerability-related events, immune responses to the drug, and several measures of asthma symptoms and quality of life over time. The reported data shows that, among participants who previously rec...
-
NCT05660850 · results posted 16 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05660850) involved 49 people in the main part of the study (Part A), split into two groups in a "crossover" design — meaning each person received both the study drug (GDC-6599) and a dummy treatment (placebo) at different points in time, so they acted as their own comparison. A very small pilot group (Part B) included just 2 people. The trial was mainly measuring how often participants coughed over a 24-hour period, recorded by a wearable device called the VitaloJAK®. It also looked at how severe participants felt their co...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03560466 · results posted 21 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03560466) involved 378 participants in total. The main study enrolled 365 people split into two groups: 125 who received a placebo first and then switched to the study drug dupilumab, and 240 who received dupilumab throughout. A smaller sub-study based in Japan enrolled 13 additional participants, all of whom received dupilumab. The trial was measuring, among other things, how many people experienced unwanted medical events during treatment (called treatment-emergent adverse events), how well participants could breathe out...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03545906 · results posted 8 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03545906) involved 326 participants in total, split into two groups of 163 people each. One group received the TEAM-UP intervention, while the other received what was called "enhanced care" for comparison. The trial tracked a condition's symptoms over time, with the main thing being measured being the average number of days out of the previous 14 days that participants were free of symptoms. The reported data shows that across four separate measurement points during the study, the TEAM-UP intervention group reported the f...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05292586 · results posted 4 September 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 576 participants in total — 287 in the CHF 1535 pMDI group and 289 in the CHF 718 pMDI group. The trial was comparing two inhaler treatments over 12 weeks in people with a breathing condition. The main thing being measured was lung function, specifically a test called FEV1 (how much air a person can forcefully breathe out in one second), tracked over a 12-hour period after taking the inhaler. A total of 276 participants completed the study in the CHF 1535 group and 267 in the CHF 718 group. The reported data shows th...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04643158 · results posted 28 August 2025
According to the results reported on ClinicalTrials.gov, this trial tested an inhaled medicine called AZD1402 in adults with asthma. It was run in two parts. Part 1 included 50 people split across three different dose levels of AZD1402 or a placebo (a dummy treatment with no active ingredient), and focused on tracking unwanted events (called adverse events) that participants experienced. Part 2 included 22 people across two dose levels of AZD1402 or a placebo, and focused on measuring a breathing test called FEV1 — which measures how much air a person can forcefully breathe out in one second —...
-
NCT05457855 · results posted 11 August 2025
According to the results reported on ClinicalTrials.gov, this trial looked at whether there was a difference in the rate of dementia diagnoses — including Alzheimer's disease and other forms of dementia — among people taking one of two existing medications: montelukast (commonly used for asthma and allergies) or fluticasone (a steroid inhaler). Around 12,575 people were in the montelukast group and 38,958 were in the fluticasone group at the start. By the end of the study period, 12,572 people from each group were counted as having completed the study. The trial used existing health records ra...
-
NCT03927157 · results posted 1 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03927157) enrolled 400 adults with asthma — 201 received tezepelumab (210 mg every four weeks by injection) and 199 received a placebo (an inactive treatment). The trial ran for 52 weeks and was primarily measuring how often participants had asthma flare-ups (called "exacerbations") over the course of a year. It also measured several secondary things, including a lung function test, asthma symptom scores, asthma control scores, and quality of life scores. By the end of the study, 186 people in the tezepelumab group and 168...
-
NCT04007198 · results posted 18 April 2025
According to the results reported on ClinicalTrials.gov, this trial involved 18 people in total, split across three groups: 7 received a lower dose of the study drug EQ001 (0.8 mg/kg), 7 received a higher dose (1.6 mg/kg), and 4 received a placebo (an inactive substance used for comparison). Of those who started, 16 completed the study — one person from each of the two active-dose groups did not finish, while all four placebo participants completed it. The trial was primarily measuring how many participants experienced unwanted health events (called "adverse events") that appeared after receiv...
-
NCT05552508 · results posted 25 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05552508) enrolled 45 people who were all given a medicine called benralizumab. Of those, 42 completed the study and 3 did not. There was only one group — everyone received the same treatment — so there was no comparison group. The trial was measuring changes in the airways over 13 weeks, using a specialised type of lung imaging to look at things like mucus (sticky fluid that can block airways), air trapping (air getting stuck in the lungs), and the size of the airways. The reported data shows the following changes from t...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04728711 · results posted 17 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04728711) enrolled 8 people with asthma, split into two groups of 4. It was a crossover study, meaning each person received both the investigational drug ADX-629 and a placebo (a dummy treatment) at different times. Seven of the 8 participants completed the study; one person in the "placebo first" group did not finish. The trial was measuring serious unwanted health events (called serious adverse events) as its main focus, and also tracked asthma control, and levels of certain immune cells in mucus samples collected after...
-
NCT04718103 · results posted 29 November 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04718103) enrolled 263 people in the GSK3511294 group and 134 people in the placebo (dummy treatment) group, with 233 and 117 respectively completing the full 52 weeks. The trial was measuring how often participants had serious asthma flare-ups over one year, as well as several other things including quality of life, asthma symptom control, lung function (how much air a person can forcefully breathe out in one second), and daily and nightly symptom scores. The reported data shows that, for the main measure — serious asthm...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03032159 · results posted 1 November 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03032159) involved 221 participants split into two groups — 110 people in the Control Group and 111 people in the Text2Breathe Study Group. The trial was looking at a text message-based program (Text2Breathe) for parents of children with asthma, and it measured things like how often children visited the emergency department for asthma, how many days they experienced asthma symptoms, how often they saw their regular doctor for asthma care, and how well parents understood asthma self-management and felt confident communicati...
-
NCT05036733 · results posted 23 October 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 15 participants, all of whom completed the study — none dropped out. All 15 received the medication dupilumab. The trial was measuring how the community of bacteria living in the airways (called the respiratory microbiota) changed over time while participants were taking dupilumab. To do this, researchers collected sputum (mucus coughed up from the lungs) at three points: before starting the medication (baseline), after 1 month, and after 4 months. They used two different ways of measuring the bacterial community — on...
-
NCT05791565 · results posted 23 September 2024
According to the results reported on ClinicalTrials.gov, this trial involved 28 people in total, split into two groups of 14. It was a "crossover" study, meaning everyone tried both versions of a salbutamol inhaler — one using a propellant called HFA-152a and one using the more traditional propellant HFA-134a — with a washout break of at least 72 hours in between. The trial was mainly measuring how much of the medicine salbutamol entered the bloodstream and how quickly, by taking blood samples and tracking the drug's levels over time. One participant did not complete the washout period and did...
-
NCT03562195 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03562195) enrolled 300 people with asthma — 149 received mepolizumab (100mg) and 151 received a placebo (a dummy treatment with no active ingredient). The trial ran for 52 weeks and was primarily measuring how often participants experienced serious asthma flare-ups — defined as episodes bad enough to need steroid tablets, a hospital visit, or an emergency department visit. The reported data shows that, on average, people in the mepolizumab group had 0.45 such flare-ups per year, compared with 1.31 per year in the placebo...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04908384 · results posted 21 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04908384) involved children with asthma and their parents, split into two groups: one that received the IMPACT intervention and one that received usual care. A total of 21 children and 21 parents started in the intervention group, and 31 children and 31 parents started in the usual care group. The trial was measuring two main things: how responsibility for asthma management was shared between parents and children, and how confident (self-efficacious) both parents and children felt in managing asthma — tracked at the start...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04981717 · results posted 11 June 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 446 people — 222 in the placebo group and 224 in the REGN1908-1909 group. The trial was measuring symptoms related to what appears to be an allergic condition, comparing a medicine called REGN1908-1909 against a placebo (an inactive treatment). The main thing being measured was a combined daily score that added together how severe a person's symptoms were and how much symptom-relieving medication they needed, known as the Combined Symptom and Medication Score (CSMS), on a scale from 0 (no symptoms or medication) to 38...
-
NCT02062463 · results posted 22 March 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02062463) had two stages. In Stage 1, around 485 people took part in a crossover comparison of two inhaler devices — an empty Spiromax and an empty Turbohaler — to see how easily people could learn to use them correctly through a step-by-step training process. In Stage 2, 197 people used a budesonide/formoterol (BF) Spiromax inhaler and 197 used a Symbicort Turbohaler over 12 weeks, to see how many could continue using the devices correctly after that time. The reported data shows that in Stage 1, 94.4% of participants re...
-
NCT02910401 · results posted 9 January 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02910401) enrolled three groups of participants: 6 people with asthma, 17 people with allergic rhinitis (hay fever), and 15 healthy volunteers — 38 people in total. The study was looking at what happens when participants were exposed to rhinovirus (the common cold virus), specifically measuring the symptoms they experienced afterwards, such as a blocked nose, nasal discharge, cough, and facial pain or pressure. Not everyone finished the study — 1 person in the asthma group and 2 in the healthy volunteer group did not compl...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01803555 · results posted 8 December 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 605 people in total — 303 in the BF Spiromax group and 302 in the Symbicort Turbohaler group. The trial was comparing these two inhaler treatments over 12 weeks in people with asthma. The main thing being measured was a breathing test called Peak Expiratory Flow (PEF) — essentially how fast a person can breathe out forcefully — recorded by participants each morning before taking their medication. Changes in evening PEF readings, adverse events (unwanted medical occurrences during the trial), and signs of oral thrush (...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01027143 · results posted 8 September 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT01027143) involved 98 children in total — 77 were given omega-3 fatty acids and 21 were in the control group (meaning they did not receive the omega-3 supplement). Of those who started, 68 in the omega-3 group and 17 in the control group completed the trial. The study was measuring asthma control in children, using several different tools including questionnaires, a breathing test, and blood and urine samples taken over the course of the trial. The reported data shows that on the main measure — the Asthma Control Question...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04589663 · results posted 27 July 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04589663) enrolled 24 adult participants, and all 24 completed the study with none dropping out. The trial was designed to compare how much of a medicine called mometasone furoate (an inhaled corticosteroid) entered the bloodstream when it was delivered by two different inhaler devices — an existing device called the Twisthaler, and a newer device called Concept 1 (which also contained a second medicine, indacaterol). Researchers measured the levels of these medicines in participants' blood at various time points to unders...
-
NCT03734861 · results posted 7 April 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 75 children in total — 50 in the BreatheSmart System group (a digital inhaler feedback tool) and 25 in the Standard of Care group (usual treatment without the device). All 75 participants completed the study. The trial was measuring how well children took their asthma medication over six months, along with several other things including asthma symptom control, a breathing test result, emergency room visits, and days missed from school. The reported data shows that for the main measure — medication adherence calculate...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 179 reported results for Asthma
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, asthma currently attracts a very large amount of public research investment from the United States government, and that investment has remained broadly steady from one year to the next. For patients, this signals that asthma is a well-established research priority that continues to draw sustained scientific attention. A consistent funding pattern like this tends to s...
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.